Valneva SE
PAR:VLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Controladora Vuela Compania de Aviacion SAB de CV
NYSE:VLRS
|
MX |
Valneva SE
EPS (Diluted)
Valneva SE
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Valneva SE
PAR:VLA
|
EPS (Diluted)
€0
|
CAGR 3-Years
18%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
EPS (Diluted)
-€1
|
CAGR 3-Years
-53%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-10%
|
|
|
Inventiva SA
PAR:IVA
|
EPS (Diluted)
-€1
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
EPS (Diluted)
$0
|
CAGR 3-Years
34%
|
CAGR 5-Years
19%
|
CAGR 10-Years
0%
|
|
|
DBV Technologies SA
PAR:DBV
|
EPS (Diluted)
-$1
|
CAGR 3-Years
5%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Abivax SA
PAR:ABVX
|
EPS (Diluted)
-€4
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
Valneva SE
Glance View
Valneva SE is a biotech company. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 722 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
See Also
What is Valneva SE's EPS (Diluted)?
EPS (Diluted)
-0.7
EUR
Based on the financial report for Dec 31, 2025, Valneva SE's EPS (Diluted) amounts to -0.7 EUR.
What is Valneva SE's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-9%
Over the last year, the EPS (Diluted) growth was -750%. The average annual EPS (Diluted) growth rates for Valneva SE have been 18% over the past three years , 1% over the past five years , and -9% over the past ten years .
